Marc Ullman was quoted in a Natural Products Insider article, “The Vitamin Shoppe to carry CBD following FDA’s move to exercise ‘enforcement discretion.'” The article discusses the FDA’s announcement to exercise “enforcement discretion” related to foods and supplements containing CBD as a factor driving mass-market retailer activity in the category, including The Vitamin Shoppe’s recent move

On April 10, 2019, Marc Ullman and Steven Shapiro will be featured speakers at Supplyside East, presenting on the topic, “What Is the Regulatory Current State of Play with CBD?”

The pair will discuss the latest insights around regulatory issues related to cannabidiol at the international, national and local levels.

Supplyside East, which bills itself

Dr. Scott Gottlieb, who announced his plan to resign as FDA commissioner on March 5, 2019, had in the previous week just announced plans to develop a regulatory framework for CBD.

Marc Ullman spoke with Nutraingredients-USA about what might happen with the CBD initiative for the article entitled “Advocates hopeful that Gottlieb’s departure won’t derail

Marc Ullman was quoted in a Nutraingredients-USA article, “Gottlieb: FDA plans meeting in April on new CBD regulations.” FDA Commissioner Scott Gottlieb said the agency is planning a public meeting in April to initiate a rule making procedure on CBD.

Click here to read the article.

On March 13, 2019, Marc Ullman will be a presenter in an EAS Consulting Group webinar entitled “What Does the 2018 Farm Bill Mean for the Cannabis Industry?” The webinar will offer an informative discussion on the FDA’s position on cannabis and how the patchwork of state regulations makes the topic confusing.

Accompanying Marc will

Marc Ullman was quoted in the Nutraingredients-USA article, “Hemp and CBD in pet supplements weaves same tangled web as in products meant for humans.” The focus of the article is the regulatory gray area for hemp and CBD in supplements intended for animals.

Ullman noted, “FDA has been very quiet in this area. CB in pet

On January 15, Marc Ullman will be speaking at the New York State Bar Association’s “Hot Topics in Cannabis Law 2019: What Lawyers Need to Know.”

He will be speaking on the topic of “CBD: What is it and What it Can Be.”

1. 0 CLE credit in the Areas of Professional Practice being offered.

Marc Ullman was interviewed for a January 2, 2019, article in Life Science Leader magazine entitled “The Unique Challenges Facing Cannabis-based Pharma.” The story covers the lengthy process to get Epidiolex, the first ever pharmaceutical derived from cannabis, approved for medical use.

Marc noted that GW Pharmaceuticals, which developed Epidiolex, was successful because it is

On December 14, Marc Ullman will be participating in the Hemp CBD Legal Roundtable at the Governor’s Office in NYC.

The roundtable will be facilitated by Axel Bernabe, Assistant Counsel to the Governor, Scott Wyner, General Counsel of the Department of Agriculture and Markets, and Brian Malkin, Co-Chair of the New York State Bar Association’s

Marc Ullman was quoted in a Natural Products Insider article, “FDA warns drug manufacturer marketing CBD products.”

According to FDA, all CBD products sold as supplements are noncompliant, said Ullman.

“But they [FDA officials] are using their discretion for now and acting only against the products making illegal drug claims,” Ullman informed. “The thing about enforcement discretion